1. Commentary: We still need observational studies of drugs—they just need to be better
2. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
3. Channeling bias in the interpretation of drug effects
4. Evaluating surrogate endpoints
5. Phillips A, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25–28, 2007.